Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company’s product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
Metrics to compare | ARMP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARMPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.6x | −1.7x | −0.6x | |
PEG Ratio | 0.05 | 0.11 | 0.00 | |
Price/Book | −2.3x | 10.9x | 2.6x | |
Price / LTM Sales | 43.1x | 51.7x | 3.3x | |
Upside (Analyst Target) | 55.2% | 174.7% | 41.4% | |
Fair Value Upside | Unlock | 10.0% | 6.0% | Unlock |